PLXMEDIUM SIGNALFINANCIAL10-K

PLX shows meaningful expansion in R&D spending alongside inventory buildup while cash reserves declined moderately.

The company appears to be investing substantially more in research and development activities while building inventory levels, suggesting preparation for expanded operations or new product launches. The combination of higher R&D spending and inventory growth, coupled with declining cash, indicates PLX is in an active investment phase that warrants monitoring of cash burn rates and development milestones.

Comparing 2026-03-18 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

PLX's financial position reflects active investment and expansion, with R&D expenses growing substantially while inventory increased by 21% to $25.7M. Cash and equivalents declined to $14.7M from $19.8M, though this was offset by overall asset growth of 12% to $82.3M and stockholders' equity expanding to $48.2M. The financial profile suggests a company investing heavily in development while maintaining a stable balance sheet structure.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+50.9%
$13.0M$19.6M

R&D investment increased 50.9% — signals commitment to future product development, though near-term margin impact.

Capital Expenditure
Cash Flow
+27.8%
$1.3M$1.6M

Capex increased 27.8% — ongoing investment in capacity or infrastructure for future growth.

Cash & Equivalents
Balance Sheet
-25.7%
$19.8M$14.7M

Cash decreased 25.7% — monitor burn rate and upcoming capital needs.

Inventory
Balance Sheet
+21.1%
$21.2M$25.7M

Inventory built 21.1% — monitor whether demand supports this build or if write-downs may follow.

Total Liabilities
Balance Sheet
+12.9%
$30.2M$34.1M

Liabilities increased 12.9% — monitor debt-to-equity ratio and interest coverage.

Total Assets
Balance Sheet
+12.2%
$73.4M$82.3M

Asset base grew 12.2% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+11.6%
$43.2M$48.2M

Equity base grew 11.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Current Assets
Balance Sheet
+11%
$60.1M$66.7M

Current assets grew 11% — improving short-term liquidity or inventory/receivables build.

LANGUAGE CHANGES
NEW — 2026-03-18
PRIOR — 2025-03-17
ADDED
On March 1, 2026, approximately 80,571,642 shares of the Registrant s common stock, par value $0.001 per share, were outstanding.
Market for Registrant s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 59 Item 6.
and its consolidated subsidiary, and Protalix or Protalix Ltd.
These and other risks and uncertainties are detailed under the Risk Factors section of this Annual Report and are described from time to time in the reports we file with the U.S.
Business We are a commercial stage biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs.
+7 more — sign up free →
REMOVED
On March 14, 2025, approximately 78,032,585 shares of the Registrant s common stock, par value $0.001 per share, were outstanding.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 63 Item 6.
and its consolidated subsidiaries, and Protalix or Protalix Ltd.
Business We are a commercial stage biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced via our proprietary ProCellEx plant cell-based protein expression system.
Our unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →